文献速递癫痫神经重症与神经感染

氯胺酮用于新生儿和儿童难治性癫痫持续状态的管理

Ketamine for Management of Neonatal and Pediatric Refractory Status Epilepticus.
PubMed 文献 · Neurology · 2022-07-11

该回顾性单中心队列研究纳入69例接受氯胺酮输注治疗的难治性癫痫持续状态患儿(含13例新生儿),仅3例(4%)出现需干预的不良事件,32例(46%)癫痫终止、19例(28%)发作减少、18例(26%)无变化,作者认为需进一步数据比较一线与后续麻醉药物治疗。

要点

  • 69例患儿中仅3例(4%)出现需干预的不良事件:高血压2例、谵妄1例。
  • 氯胺酮输注后32例(46%)癫痫终止、19例(28%)发作减少、18例(26%)无变化。
  • 研究提供IV级证据,作者认为需进一步数据比较一线与后续麻醉药物治疗。

核心结论

  • 氯胺酮给药与少量不良事件相关,且给药后癫痫常终止或改善。
  • 需要进一步数据比较一线与后续麻醉药物治疗儿童和新生儿难治性癫痫持续状态。
  • 本研究提供IV级证据支持氯胺酮用于儿童和新生儿难治性癫痫持续状态的治疗效用。

研究设计与样本

  • 回顾性单中心队列研究,连续纳入某四级儿童医院重症监护室接受氯胺酮输注治疗难治性癫痫持续状态的患者。
  • 共69例患者接受氯胺酮输注治疗难治性癫痫持续状态,其中新生儿13例(19%)。
  • 难治性癫痫持续状态起病中位年龄为0.7岁(四分位距0.15-7.2)。

主要发现

  • 3例(4%)在氯胺酮给药期间或给药后12小时内出现需干预的不良事件,包括高血压2例和谵妄1例。
  • 氯胺酮输注后癫痫终止32例(46%),发作减少19例(28%),无变化18例(26%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Few data are available regarding the use of anesthetic infusions for refractory status epilepticus (RSE) in children and neonates, and ketamine use is increasing despite limited data. We aimed to describe the impact of ketamine for RSE in children and neonates. METHODS: Retrospective single-center cohort study of consecutive patients admitted to the intensive care units of a quaternary care children's hospital treated with ketamine infusion for RSE. RESULTS: Sixty-nine patients were treated with a ketamine infusion for RSE. The median age at onset of RSE was 0.7 years (interquartile range 0.15-7.2), and the cohort included 13 (19%) neonates. Three patients (4%) had adverse events requiring intervention during or within 12 hours of ketamine administration, including hypertension in 2 patients and delirium in 1 patient. Ketamine infusion was followed by seizure termination in 32 patients (46%), seizure reduction in 19 patients (28%), and no change in 18 patients (26%). DISCUSSION: Ketamine administration was associated with few adverse events, and seizures often terminated or improved after ketamine administration. Further data are needed comparing first-line and subsequent anesthetic medications for treatment of pediatric and neonatal RSE. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence on the therapeutic utility of ketamine for treatment of RSE in children and neonates.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jacobwitz M, Mulvihill C, Kaufman MC, et al. Ketamine for Management of Neonatal and Pediatric Refractory Status Epilepticus. Neurology. 2022. PMID: 35817569. doi:10.1212/WNL.0000000000200889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。